Center on Health Equity & Access

Learn what sickle cell disease is, who it affects most, today’s treatment options, and how cost and inequities limit access.

To conclude his conversation with AJMC, Jordan Karlitz, MD, outlines clinical, behavioral, and policy strategies to reverse rising CRC deaths in adults aged under 50.

Advances in sickle cell therapies, including gene editing, offer hope—but racial disparities, cost, and access barriers remain major challenges.

Oral GLP-1 costs, insurance gaps, and formulary switches reshape drug pricing and access—learn how to navigate coverage.

Providing monthly produce prescriptions to patients with diabetes at risk for food insecurity did not significantly improve cardiometabolic parameters.

Jordan Karlitz, MD, highlights racial, ethnic, and socioeconomic disparities in rising CRC mortality rates among younger adults, driven by gaps in screening and awareness.

NHANES data reveal a US sleep crisis: Chronic sleep deprivation gaps tied to education, BMI, and food security, via Blinder-Oaxaca decomposition.

New reports reveal rising insurance costs, senior drug savings, and cancer care inequities, showing how policy and partnerships shape health outcomes.

Sarah M. Lima, PhD, MPH, on how historical redlining continues to shape breast cancer survival disparities through treatment access and innovation.

Ricciuti explains why advanced adoptive cell therapies require major infrastructure, toxicity management, and strong academic–community collaboration.

Study finds breast cancer survival gaps tied to historical redlining narrowed over time, though newer therapies may be widening disparities again.

Biagio Ricciuti, MD, discusses how access challenges and toxicity concerns slow the rollout of new T-cell engager therapies from academic centers into community oncology.

Anasuya Gunturi, MD, PhD, explains how academic–community partnerships help deliver complex oncology services closer to home.

As more oral cancer therapies become available, medically integrated dispensing models are increasingly vital, says Kenneth Komorny, PharmD, BCPS.

Andrew Yee, MD, explains how academic centers can share practical oncology best practices that community hospitals can implement sustainably.

Susan Vadaparampil, PhD, MPH, explains that aligning clinical trials with community needs can improve enrollment diversity.

Community-academic collaboration can reduce access burdens and strengthen continuity of care, says Anasuya Gunturi, MD, PhD.

Poland’s senior prescription subsidies cut drug costs and catastrophic pharmacy spending for adults aged 75 or older.

A Commonwealth Fund analysis finds employer health premiums and deductibles exceed 10% of income in 19 states, worsening affordability gaps.

PBM reforms, Medicare Advantage trends, TrumpRx launch, and Express Scripts settlement highlight key shifts in drug pricing, coverage, and patient access.

A survey found many patients with long-term conditions prefer remote visits for results and refills, but some trade continuity for faster care.

Ameet Patel, MD, discusses scaling CAR T-cell therapy and bispecific therapies to improve access and potentially cure multiple myeloma.

Vishal A. Patel, MD, explains that delayed skin cancer diagnoses contribute to more advanced disease and poorer outcomes in patients with darker skin.

Medically integrated dispensing (MID) models help build patient trust in pharmacists, which can help improve adherence, explains Kenneth Komorny, PharmD, BCPS.

Community partnerships and trial design reforms can reduce travel barriers and improve underserved patient representation, said Amir Fathi, MD.